Overview

PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a Randomized, open-label, single-dose, 2-treatment, 2-period, 2-sequence crossover design.
Phase:
Phase 1
Details
Lead Sponsor:
Yuhan Corporation
Treatments:
Amlodipine
Chlorthalidone
Telmisartan
Telmisartan amlodipine combination